Raymond James Financial
BCYC

Raymond James Financial’s Bicycle Therapeutics BCYC Stock Holding History

Raymond James Financial’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,336
Closed -$87.3K – 5299
2025
Q4 		$87.3K Buy
+12,336
New +$91K ﹤0.01% 4951
2025
Q3 		– Sell
-1,933
Closed -$13.4K – 5139
2025
Q2 		$13.4K Buy
+1,933
New +$15.4K ﹤0.01% 5778

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial's BCYC Position: Q1 2026 in Review

Raymond James Financial sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 12,336 shares — an estimated $87.3K sold.

Raymond James Financial first reported a position in BCYC in Q2 2025 and held it in 2 quarters. The position peaked at $87.3K in Q4 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Raymond James Financial reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 12,336 Bicycle Therapeutics shares in Q1 2026, an estimated $87.3K.
  • Raymond James Financial first reported a position in Bicycle Therapeutics in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Bicycle Therapeutics position peaked at $87.3K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.